ARDS.US Aridis Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 13, 2026
0.0001 0.0150
Market cap
USD 4.46K
P/E
-
P/B
5.40x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.

Is ARDS.US undervalued?

Graham number

The Graham number of Aridis Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Aridis Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Aridis Pharmaceuticals Inc yet.

Aridis Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to …

Full company profile